Back to Newsroom

Strand Life Sciences Set to Introduce Expanded StrandAdvantage Genomic Profiling Service at 2015 ASCO Annual Meeting

AURORA, Colo., May 27, 2015Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced it will introduce its expanded StrandAdvantage pan-cancer genomic profiling service later this month at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The new version of StrandAdvantage will include a panel that examines 152 genes — all genes and pathways known to be impacted by existing targeted cancer therapies plus additional chemotherapeutic toxicity and resistance data.

Click here to read more